

EudraCT Number: 2010-021146-22

Alemtuzumab and rheumatoid arthritis – an immunisation study

This document contains mortality and morbidity data for participants in the original Alemtuzumab cohort 1991-1994, which is a secondary outcome for the present study.

Table A

Age at Death	Cause of Death
78	Carcinomatosis, Unknown Primary, Rheumatoid Arthritis
79	Bronchopneumonia, Rheumatoid Arthritis, Cellulitis
58	Respiratory Failure, Pulmonary Oedema
89	Bronchopneumonia, Congestive Cardiac Failure
77	Pneumonia, Vascular Dementia
71	Brain Tumour
76	Sepsis, Urinary Tract Infection, Chronic Obstructive Pulmonary Disease, Rheumatoid Arthritis
69	Adenocarcinoma of the lung
79	Pulmonary fibrosis
75	Dementia, Rheumatoid Arthritis

Table A: Mortality from March 9th 2006 (last follow-up of original cohort) through to January 1st 2015 in rheumatoid arthritis (RA) patients who had received alemtuzumab between 1991-1994

Table B

All deaths	n=37	Primary cause of death
Cardiovascular and atherosclerotic disease	n=12	Ischaemic heart disease (n=8), respiratory compromise secondary to heart failure (n=1), multi infarct dementia (n=1), bowel infarction secondary to atrial fibrillation (n=1), superior mesenteric artery infarction (n=1)
Infection	n=11	respiratory (n=10) renal tract (n=1)
Malignancy	n=8	Lung primary (n=3), non-Hodgkin's lymphoma (n=1), breast primary (n=1), brain tumour (n=1), stomach leiomyosarcoma (n=1), unknown primary (n=1)
Other	n=6	Non-malignant gastrointestinal tract perforation (n=2), pulmonary fibrosis (n=1), dementia (n=1), upper gastrointestinal bleed (n=1), primary sclerosing cholangitis (n=1)

Table B: Mortality from 1994 – January 1st 2015 in rheumatoid arthritis (RA) patients that had been treated with alemtuzumab between 1991-1994.